Illustration: Shutterstock

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

A half-decade af­ter a sci­en­tist’s reck­less ex­per­i­ment with hu­man em­bryos put a stop to much of Chi­na’s clin­i­cal work on CRISPR gene edit­ing, lo­cal re­searchers …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.